Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Ginkgo Bioworks
DNA
|
$1.05B |
| 2 |
Peloton Interactive
PTON
|
$691M |
| 3 |
DoorDash
DASH
|
$456M |
| 4 |
Certara
CERT
|
$393M |
| 5 |
Service Corp International
SCI
|
$374M |
Top Sells
| 1 |
Alibaba
BABA
|
$2.33B |
| 2 |
Tesla
TSLA
|
$1.55B |
| 3 |
Moderna
MRNA
|
$1.41B |
| 4 |
Amazon
AMZN
|
$884M |
| 5 |
NetEase
NTES
|
$692M |
Sector Composition
| 1 | Consumer Discretionary | 27.71% |
| 2 | Healthcare | 26.02% |
| 3 | Technology | 19.32% |
| 4 | Communication Services | 12.04% |
| 5 | Financials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
ON Semiconductor
ON
$19.5B
| $23K | ﹤0.01% |
+500
| New | +$23K |
|
352
W.W. Grainger
GWW
$48.7B
| $23K | ﹤0.01% |
+59
| New | +$23K |
|
353
Celsius Holdings
CELH
$15.8B
| $23K | ﹤0.01% |
260
| – | – |
|
354
Box
BOX
$4.69B
| $23K | ﹤0.01% |
979
| – | – |
|
355
Avery Dennison
AVY
$13B
| $23K | ﹤0.01% |
110
| – | – |
|
|
ZNGA
356
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $22K | ﹤0.01% |
2,863
-564
| -16% | -$4.33K |
|
|
SGEN
357
DELISTED
Seagen Inc. Common Stock
SGEN
| $22K | ﹤0.01% |
128
| – | – |
|
358
XPEL
XPEL
$973M
| $22K | ﹤0.01% |
295
-47
| -14% | -$3.51K |
|
359
Progyny
PGNY
$2.02B
| $22K | ﹤0.01% |
396
| – | – |
|
360
Pfizer
PFE
$141B
| $22K | ﹤0.01% |
+500
| New | +$22K |
|
361
Knowles
KN
$1.8B
| $22K | ﹤0.01% |
+1,200
| New | +$22K |
|
362
Humana
HUM
$37.5B
| $22K | ﹤0.01% |
56
-2
| -3% | -$786 |
|
363
Cohu
COHU
$899M
| $22K | ﹤0.01% |
+700
| New | +$22K |
|
364
BioCryst Pharmaceuticals
BCRX
$1.74B
| $22K | ﹤0.01% |
+1,500
| New | +$22K |
|
|
GBT
365
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $21K | ﹤0.01% |
835
-119
| -12% | -$2.99K |
|
|
MNTV
366
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $21K | ﹤0.01% |
1,095
| – | – |
|
|
SMAR
367
DELISTED
Smartsheet Inc.
SMAR
| $21K | ﹤0.01% |
311
-42
| -12% | -$2.84K |
|
368
Nutanix
NTNX
$18.2B
| $21K | ﹤0.01% |
563
-58
| -9% | -$2.16K |
|
369
Medifast
MED
$153M
| $21K | ﹤0.01% |
110
-19
| -15% | -$3.63K |
|
370
Logitech
LOGI
$15.4B
| $21K | ﹤0.01% |
235
-30
| -11% | -$2.68K |
|
371
Quest Diagnostics
DGX
$20.1B
| $21K | ﹤0.01% |
145
-15
| -9% | -$2.17K |
|
372
Boston Omaha
BOC
$425M
| $21K | ﹤0.01% |
529
| – | – |
|
373
Rollins
ROL
$27.3B
| $20K | ﹤0.01% |
562
-43
| -7% | -$1.53K |
|
374
Quaker Houghton
KWR
$2.34B
| $20K | ﹤0.01% |
86
| – | – |
|
375
CommScope
COMM
$3.57B
| $20K | ﹤0.01% |
1,442
-101
| -7% | -$1.4K |
|